<DOC>
	<DOCNO>NCT00159822</DOCNO>
	<brief_summary>To evaluate efficacy voriconazole ( VFend ( R ) ) first line treatment proven chronic bronchopulmonary aspergillosis , minimally immunocompromised non-immunocompromised patient 6 month treatment i.e . chronic necrotizing pulmonary</brief_summary>
	<brief_title>Voriconazole For Chronic Bronchopulmonary Aspergillosis</brief_title>
	<detailed_description />
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Pulmonary Aspergillosis</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>Patients chronic bronchopulmonary aspergillosis assess compatible chest imagery ( CT scan ) and/or endoscopic lesion source photo , would : Complex aspergilloma non primarily operable , Chronic necrotizing pulmonary aspergillosis , Tracheobronchial aspergillosis , obstructive necrotizing/pseudomembranous . Patient risk factor ( ) cardiac arrhythmia , symptomatic arrhythmia , treated medication know prolong QT interval , prolongation QTc interval &gt; 450 msec men &gt; 470 msec woman . Simple aspergilloma primary indication surgical treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>